The present invention provides compositions and methods for reducing microbial and nematodal contamination or infection in plants, animals, fabrics, and products therefrom. The present invention also provides compositions and methods for reducing human infections and the emergence of antimicrobial resistance. In particular, the invention provides magnetic nanoparticles comprising biocidal or biostatic enzymes in one component, substrates for the enzymes in a second component, and a biocidal chemical agent that works in combination or synergistically with the enzymes. The compositions are dormant and become active upon exposure to hydration, oxygen, or mixing.

A polyurethane foam wound dressing, the foam integrally comprising an oxidoreductase enzyme and a substrate for the enzyme. The foam is produced by mixing a polyurethane polymer, water, an oxidoreductase enzyme and substrate for the enzyme and drying the resulting product.

A polyurethane foam wound dressing, the foam integrally comprising an oxidoreductase enzyme and a substrate for the enzyme. The foam is produced by mixing a polyurethane polymer, water, an oxidoreductase enzyme and substrate for the enzyme and drying the resulting product.

Disclosed are solid dressings for treating wounded tissue in mammalian patients, such as a human, comprising a haemostatic layer consisting essentially of a fibrinogen component and a fibrinogen activator, wherein the haemostatic layer(s) is cast or formed from a single aqueous solution containing the fibrinogen component and the fibrinogen activator. Also disclosed are methods for treating wounded tissue using these dressings and frozen compositions useful for preparing the haemostatic layer(s) of these dressings.

Disclosed are solid dressings for treating wounded tissue in mammalian patients, such as a human, comprising a haemostatic layer consisting essentially of a fibrinogen component and a fibrinogen activator, wherein the haemostatic layer(s) is cast or formed from a single aqueous solution containing the fibrinogen component and the fibrinogen activator. Also disclosed are methods for treating wounded tissue using these dressings and frozen compositions useful for preparing the haemostatic layer(s) of these dressings.

A hemostatic product that includes a fibrinogen mixture, a thrombin mixture and a biologically tolerable liquid. The fibrinogen mixture includes fibrinogen and at least one fibrinogen stabilizer. The thrombin mixture includes thrombin and at least one thrombin stabilizer. The biologically tolerable liquid is mixed with the fibrinogen mixture and the thrombin mixture to form the hemostatic product.

A hemostatic product that includes a fibrinogen mixture, a thrombin mixture and a biologically tolerable liquid. The fibrinogen mixture includes fibrinogen and at least one fibrinogen stabilizer. The thrombin mixture includes thrombin and at least one thrombin stabilizer. The biologically tolerable liquid is mixed with the fibrinogen mixture and the thrombin mixture to form the hemostatic product.

Disclosed is a dissolvable, gel-forming film, and methods for its use, comprising a water-soluble cellulose ether, a hydrophilic rheological modifying agent, and an active proteolytic enzyme or other drug substance. The gel-forming film has a water content of less than 15% w/w and is capable of forming a hydrogel when contacted with water or other aqueous medium. The disclosed films achieve delivery of stable proteolytic enzymes to the desired site of action in a manner that provides uniform delivery of the enzymes.

Disclosed is a dissolvable, gel-forming film, and methods for its use, comprising a water-soluble cellulose ether, a hydrophilic rheological modifying agent, and an active proteolytic enzyme or other drug substance. The gel-forming film has a water content of less than 15% w/w and is capable of forming a hydrogel when contacted with water or other aqueous medium. The disclosed films achieve delivery of stable proteolytic enzymes to the desired site of action in a manner that provides uniform delivery of the enzymes.

The subject invention provides topical therapeutic compositions and methods of their use for enhanced healing of wounds, including burns, and scars of the skin. Specifically, in one embodiment, the subject invention provides materials and methods for reducing the healing time of skin wounds and for reducing the appearance of scars. The subject invention utilizes topical compositions comprising microbial growth by-products and, optionally, a topically-acceptable carrier. In specific embodiments, the microbial growth by-products are biosurfactants.